[go: up one dir, main page]

FI911275A0 - Cd25-bindande molekyler. - Google Patents

Cd25-bindande molekyler.

Info

Publication number
FI911275A0
FI911275A0 FI911275A FI911275A FI911275A0 FI 911275 A0 FI911275 A0 FI 911275A0 FI 911275 A FI911275 A FI 911275A FI 911275 A FI911275 A FI 911275A FI 911275 A0 FI911275 A0 FI 911275A0
Authority
FI
Finland
Prior art keywords
antibodies
molekyler
bindande
paticularly
immunoconjugates
Prior art date
Application number
FI911275A
Other languages
English (en)
Other versions
FI103131B (fi
FI911275L (fi
FI103131B1 (fi
Inventor
Peter Lloyd Amlot
Arne Nalpon Akbar
Guenther Heinrich
Salvatore Cammisuli
Original Assignee
Sandoz Ag
Royal Free Hosp School Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI911275(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Sandoz Ag, Royal Free Hosp School Med filed Critical Sandoz Ag
Publication of FI911275A0 publication Critical patent/FI911275A0/fi
Publication of FI911275L publication Critical patent/FI911275L/fi
Priority to FI981799A priority Critical patent/FI104047B1/fi
Application granted granted Critical
Publication of FI103131B publication Critical patent/FI103131B/fi
Publication of FI103131B1 publication Critical patent/FI103131B1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI911275A 1990-03-16 1991-03-14 Menetelmä CD25 sitovan molekyylin valmistamiseksi FI103131B1 (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI981799A FI104047B1 (fi) 1990-03-16 1998-08-21 DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9005962 1990-03-16
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB9019323 1990-09-05
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (4)

Publication Number Publication Date
FI911275A0 true FI911275A0 (fi) 1991-03-14
FI911275L FI911275L (fi) 1991-09-17
FI103131B FI103131B (fi) 1999-04-30
FI103131B1 FI103131B1 (fi) 1999-04-30

Family

ID=26296798

Family Applications (3)

Application Number Title Priority Date Filing Date
FI911275A FI103131B1 (fi) 1990-03-16 1991-03-14 Menetelmä CD25 sitovan molekyylin valmistamiseksi
FI981799A FI104047B1 (fi) 1990-03-16 1998-08-21 DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
FI19991788A FI19991788A7 (fi) 1990-03-16 1999-08-23 CD25 sitovia molekyylejä

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI981799A FI104047B1 (fi) 1990-03-16 1998-08-21 DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
FI19991788A FI19991788A7 (fi) 1990-03-16 1999-08-23 CD25 sitovia molekyylejä

Country Status (23)

Country Link
US (2) US6521230B1 (fi)
EP (1) EP0449769B1 (fi)
JP (1) JP2585475B2 (fi)
AT (1) ATE98655T1 (fi)
AU (1) AU635401B2 (fi)
CA (1) CA2038279C (fi)
CY (1) CY1977A (fi)
DE (2) DE19975033I2 (fi)
DK (1) DK0449769T3 (fi)
ES (1) ES2061216T3 (fi)
FI (3) FI103131B1 (fi)
HK (1) HK53797A (fi)
HU (2) HUT60768A (fi)
IE (1) IE65062B1 (fi)
IL (1) IL97545A (fi)
LU (1) LU90383I2 (fi)
MY (1) MY106161A (fi)
NL (1) NL990008I2 (fi)
NZ (1) NZ237434A (fi)
PL (1) PL170321B1 (fi)
PT (1) PT97034B (fi)
SA (1) SA92120358B1 (fi)
TW (1) TW213486B (fi)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
CA2123307A1 (en) * 1991-11-26 1993-06-10 Phillip M. Friden Process for the preparation of transferrin receptor specific antibody-neuro-pharmaceutical or diagnostic agent conjugates
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7365369B2 (en) 1997-06-11 2008-04-29 Nichia Corporation Nitride semiconductor device
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU5728699A (en) * 1998-07-27 2000-02-21 Amlot, Peter Lloyd Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
MXPA03009115A (es) 2001-04-06 2004-11-22 Univ Bristol Uso de moleculas de enlace de cd25 en pacientes resistentes a esteroides.
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
DK1578397T3 (da) 2002-11-15 2013-03-11 Genmab As Humane monoklonale antistoffer mod CD25
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
JP2007531707A (ja) * 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
DK2270050T3 (da) * 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
KR20100135807A (ko) 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
CN102027018A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
EP2265643B1 (en) 2008-03-13 2016-10-19 Biotest AG Dosing regimen for treating psoriasis and rheumatoid arthritis
EP2493922B1 (en) 2009-10-26 2017-02-15 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2839860B1 (en) 2012-10-12 2019-05-01 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014140174A1 (en) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
AU2018253950A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
US12325751B2 (en) 2019-06-10 2025-06-10 Shandong Boan Biotechnology Co., Ltd. Anti-CD25 antibody and application thereof
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022221669A1 (en) 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
KR20250029874A (ko) 2022-07-01 2025-03-05 뉴로진 인크. T-조절 세포를 우선적으로 자극하기 위한 neo-2/15 변이체 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
DE3850750T2 (de) * 1987-12-02 1994-12-22 Becton Dickinson Co Verfahren zur Verhütung von GVHD.
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
DE69100768T2 (de) 1994-05-11
HU910761D0 (en) 1991-09-30
FI19991788L (fi) 1999-08-23
CY1977A (en) 1997-09-05
FI19991788A7 (fi) 1999-08-23
ATE98655T1 (de) 1994-01-15
FI103131B (fi) 1999-04-30
PT97034A (pt) 1991-10-31
SA92120358B1 (ar) 2004-01-25
EP0449769A1 (en) 1991-10-02
FI981799A0 (fi) 1998-08-21
HK53797A (en) 1997-05-02
DK0449769T3 (da) 1994-02-21
PL289436A1 (en) 1992-02-24
MY106161A (en) 1995-03-31
FI911275L (fi) 1991-09-17
FI103131B1 (fi) 1999-04-30
ES2061216T3 (es) 1994-12-01
CA2038279C (en) 1999-03-09
TW213486B (fi) 1993-09-21
HU211885A9 (en) 1995-12-28
FI104047B (fi) 1999-11-15
NZ237434A (en) 1992-08-26
PL170321B1 (pl) 1996-11-29
CA2038279A1 (en) 1991-09-17
PT97034B (pt) 1998-07-31
US6521230B1 (en) 2003-02-18
IE65062B1 (en) 1995-10-04
DE19975033I2 (de) 2007-01-04
AU635401B2 (en) 1993-03-18
NL990008I2 (nl) 1999-10-01
JPH04316600A (ja) 1992-11-06
JP2585475B2 (ja) 1997-02-26
EP0449769B1 (en) 1993-12-15
FI981799L (fi) 1998-08-21
LU90383I2 (fr) 1999-06-07
IL97545A0 (en) 1992-06-21
NL990008I1 (nl) 1999-06-01
HUT60768A (en) 1992-10-28
DE69100768D1 (de) 1994-01-27
AU7290991A (en) 1991-09-19
IE910867A1 (en) 1991-09-25
US6383487B1 (en) 2002-05-07
IL97545A (en) 2000-06-29
FI104047B1 (fi) 1999-11-15

Similar Documents

Publication Publication Date Title
DK0449769T3 (da) CD25-bindende molekyler
ATE208820T1 (de) Humanisierte antikoerper
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
GB2246781A (en) CD3 specific recombinant antibody
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
DK0448057T3 (da) Monoklonalt antistof, der reagerer med en hidtil ukendt HLA-determinant på MHC klasse I-molekyler sa mt en fremgangsmåde til aktivereing af lymfocytter
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ATE245169T1 (de) Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
ES2112869T3 (es) Anticuerpos monoclonales contra celulas de islotes del pancreas humano.
DK0476226T3 (da) Monoklonalt antistof mod humant IgE
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
ATE132906T1 (de) Neuartige antiidiotypische monoklonale antikörper
DK0472498T3 (da) Monoklone antistoffer mod Leptosphaeria.
BG51640A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

GB Transfer or assigment of application

Owner name: NOVARTIS AG

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L155

Extension date: 20131008